bioRxiv Science⌕ Search

Biology subjects

Johnsen, L.

Publications and source records attributed to Johnsen, L..

2 recordsLinked to original sources

The RecBCD complex interacts directly with the DNA sliding clamp in Escherichia coli

DNA sliding clamps are essential coordinators of genome replication and maintenance across all domains of life and serve as platforms for recruiting diverse binding partners. The bacterial DNA sliding clamp, {beta}-clamp, functions analogous to the eukaryotic proliferating cell nuclear antigen (PCNA), yet its full interactome remains incompletely characterized. Here, we identify and characterize a previously unrecognized interaction between {beta}-clamp and the DNA repair helicase-nuclease complex RecBCD, specifically through its RecB subunit. Using bacterial two-hybrid assays, co-immunoprecipitation, and fluorescence microscopy, we show that RecB physically associates with {beta}-clamp. Nuclear magnetic resonance (NMR) spectroscopy demonstrates binding to the canonical ligand binding pocket in {beta}-clamp and identifies a clamp-binding motif within the RecB nuclease domain which targeted mutagenesis abolishes. Moreover, disrupting the interaction between RecB and {beta}-clamp compromises Escherichia coli survival following DNA damage and impairs the DNA degradation activity of RecBCD. These findings expand the known {beta}-clamp interactome and uncover a possible role for {beta}-clamp in DNA double-strand break repair, offering new insights into bacterial DNA metabolism and potential avenues for therapeutic intervention. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=81 SRC="FIGDIR/small/671105v1_ufig1.gif" ALT="Figure 1"> View larger version (27K): org.highwire.dtl.DTLVardef@1aa96b9org.highwire.dtl.DTLVardef@8d80daorg.highwire.dtl.DTLVardef@6a1f0org.highwire.dtl.DTLVardef@171c1bc_HPS_FORMAT_FIGEXP M_FIG C_FIG

microbiology↗

ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder whose most debilitating pathology is progressive and cumulative heterotopic ossification (HO) of skeletal muscles, ligaments, tendons, and fascia. FOP is caused by mutations in the type I BMP receptor gene ACVR1, which enable ACVR1 to utilize its natural antagonist, Activin A, as an agonistic ligand. The physiological relevance of this property is underscored by the fact that HO in FOP is exquisitely dependent on activation of FOP-mutant ACVR1 by Activin A, an effect countered by inhibition of Activin A via monoclonal antibody treatment. Hence, we surmised that ACVR1 antibodies that block activation of ACVR1 by ligand should also inhibit HO in FOP and provide an additional therapeutic option for this condition. Therefore, we generated ACVR1 monoclonal antibodies that block ACVR1s activation by its ligands. Surprisingly, in vivo, these ACVR1 antibodies stimulate HO and activate signaling of FOP-mutant ACVR1. This property is restricted to FOP-mutant ACVR1 and results from ACVR1 antibody-mediated dimerization of ACVR1. Conversely, wild type ACVR1 is inhibited by ACVR1 antibodies. These results uncover an additional novel property of FOP-mutant ACVR1 and indicate that ACVR1 antibodies should not be considered as therapeutics for FOP.

biochemistry↗